echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > KRAS inhibitor!

    KRAS inhibitor!

    • Last Update: 2021-06-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Pharmaceutical Guanlan

    Jacos Pharmaceuticals recently announced that its research project, the KRAS G12C inhibitor JAB-21822, was approved for clinical use in China on May 27 following its recent clinical approval in the United States.


    KRAS is one of the most frequently mutated oncogenes in human cancers.


    Just today (May 29), the U.


    JAB-21822 is a class 1 small molecule anti-tumor drug independently developed by Jacos Pharmaceuticals.


    The press release pointed out that Jacosi Pharmaceuticals is committed to overcoming non-drugable targets.


    Note: The original text has been deleted

    Reference materials:

    Reference materials:

    [1] GAX KRAS G12C inhibitor IND approved in China will start a Sino-US multi-center clinical trial.


    [1] GAX KRAS G12C inhibitor IND approved in China will start a Sino-US multi-center clinical trial.


    [2] The clinical trial application for the new drug of GKRAS KRAS G12C inhibitor was approved in the United States.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.